Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.

Hydroxyurea (HU) can increase fetal hemoglobin (HbF) in sickle cell anemia (HbSS). To identify determinants of the HbF response, we studied 150 HU-treated patients grouped by quartiles of change in HbF from baseline to 2 years. Half of the HU-assigned patients had long-term increments in HbF. In the top two quartiles, HbF increased to 18.1% and 8.8%. These patients had the highest baseline neutrophil and reticulocyte counts, and largest treatment-associated decrements in these counts. In the lower two quartiles, 2-year HbF levels (4.2% and 3.9%) and blood counts changed little from baseline. In the highest HbF response quartile, myelosuppression developed in less than 6 months, compliance was best, and final doses of HU were 15 to 22.5 mg/kg. All four quartiles had substantial increases of F cells in the first year. This was maintained for 2 years only in the top three quartiles. Leukocyte and reticulocyte counts decreased initially in all quartiles, but drifted back toward baseline levels in the lowest HbF response quartile. Initial HbF level and phenotype of the F-cell production (FCP) locus were not associated with HbF response, but absence of a Central African Republic (CAR) haplotype was. Bone marrow ability to withstand HU treatment may be important for sustained HbF increases during HU treatment of HbSS.

[1]  S. Antonarakis,et al.  Nonrandom association of polymorphic restriction sites in the beta-globin gene cluster. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Charache,et al.  Flow cytometric reticulocyte counting with thioflavin T in a clinical hematology laboratory. , 1987, Archives of pathology & laboratory medicine.

[3]  Richard D Moore,et al.  Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. , 1992, Blood.

[4]  M L Terrin,et al.  Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” Agent , 1996, Medicine.

[5]  K. Betke,et al.  Estimation of small percentages of foetal haemoglobin. , 1959, Nature.

[6]  E Vichinsky,et al.  Pain in sickle cell disease. Rates and risk factors. , 1991, The New England journal of medicine.

[7]  M L Terrin,et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.

[8]  M. Keating,et al.  The long QT syndrome. A review of recent molecular genetic and physiologic discoveries. , 1996, Medicine.

[9]  T. Huisman,et al.  DNA sequence variation associated with elevated fetal G gamma globin production. , 1985, Blood.

[10]  N. Anagnou,et al.  A new gene deletion in the alpha-like globin gene cluster as the molecular basis for the rare alpha-thalassemia-1(--/alpha alpha) in blacks: HbH disease in sickle cell trait. , 1986, Blood.

[11]  W. Bell,et al.  Microscopic method for assaying F cell production: illustrative changes during infancy and in aplastic anemia. , 1978, Blood.

[12]  R. Ware,et al.  Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia , 1995, American journal of hematology.

[13]  J. Clegg,et al.  The interaction of alpha-thalassemia and homozygous sickle-cell disease. , 1982, The New England journal of medicine.

[14]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[15]  D. Labie,et al.  Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type. , 1985, The New England journal of medicine.

[16]  G. Dover,et al.  Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. , 1987, Blood.

[17]  A. Schechter,et al.  Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. , 1990, The New England journal of medicine.

[18]  D. Powars,et al.  Sickle cell anemia. Beta s gene cluster haplotypes as genetic markers for severe disease expression. , 1993, American journal of diseases of children.

[19]  N. Blin,et al.  A general method for isolation of high molecular weight DNA from eukaryotes. , 1976, Nucleic acids research.

[20]  J. Parker,et al.  Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. , 1991, Blood.

[21]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[22]  E. Fabricius,et al.  Determination of hydroxyurea in mammalian tissues and blood. , 1971, Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research.

[23]  Y. Kan,et al.  Detection of sickle cell anaemia and thalassaemias , 1987, Nature.

[24]  S. Orkin,et al.  Linkage of β-thalassaemia mutations and β-globin gene polymorphisms with DNA polymorphisms in human β-globin gene cluster , 1982, Nature.

[25]  E. Baysal,et al.  The β- and δ-Thalassemia Repository (Eighth Edition) , 1995 .

[26]  W. Schroeder,et al.  β-Cluster Haplotypes, α-Gene Status, and Hematological Data from SS, SC, and S-β-Thalassemia Patients in Southern California , 1989 .

[27]  M. Steinberg,et al.  Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. , 1984, Blood.

[28]  George J. Dover,et al.  Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments] , 1992 .

[29]  G. Dover,et al.  An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, beta-globin haplotypes, alpha-globin gene number, gender, and age. , 1995, Blood.

[30]  W. Feder,et al.  Effective Increase in Nematode Populations by the Addition of Aureomycin , 1959, Nature.

[31]  L. Benjamin,et al.  Gender and haplotype effects upon hematological manifestations of adult sickle cell anemia , 1995, American journal of hematology.

[32]  J. Niland,et al.  Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. , 1991, Annals of internal medicine.

[33]  Y. C. Chang,et al.  Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2 , 1992 .

[34]  D. Meyers,et al.  Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. , 1992, Blood.

[35]  D. Labie,et al.  Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Lathrop,et al.  Detection of a major gene for heterocellular hereditary persistence of fetal hemoglobin after accounting for genetic modifiers. , 1994, American journal of human genetics.

[37]  D. Powars.  Beta s-gene-cluster haplotypes in sickle cell anemia. Clinical and hematologic features. , 1991, Hematology/oncology clinics of North America.

[38]  H. Origasa.  Longitudinal Data Analysis Using Linear Models , 1988 .

[39]  G. Dover,et al.  Fetal hemoglobin-containing cells have the same mean corpuscular hemoglobin as cells without fetal hemoglobin: a reciprocal relationship between gamma- and beta-globin gene expression in normal subjects and in those with high fetal hemoglobin production. , 1987, Blood.

[40]  T. Ley,et al.  Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. , 1986, Blood.

[41]  R. J. Hayes,et al.  The haematology of steady state homozygous sickle cell disease: frequency distributions, variation with age and sex, longitudinal observations , 1985, British journal of haematology.

[42]  G. Dover,et al.  Individual variation in the production and survival of F cells in sickle-cell disease. , 1978, The New England journal of medicine.

[43]  Richard F. Gunst,et al.  Applied Regression Analysis , 1999, Technometrics.

[44]  K. Betke,et al.  Estimation of Small Percentages of Fœtal Hæmoglobin , 1959, Nature.

[45]  J. Smith,et al.  Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. , 1992, Journal of clinical epidemiology.

[46]  P. Lauf,et al.  Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. , 1994, Blood.

[47]  P. Dr,et al.  Sickle cell anemia: beta s-gene-cluster haplotypes as prognostic indicators of vital organ failure. , 1991, Seminars in hematology.

[48]  F. Barton,et al.  Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. , 1995, Controlled clinical trials.

[49]  A. Schechter,et al.  Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. , 1993, The New England journal of medicine.